Beyond Captopril: How Peptide Research Is Tackling the ACE Cough Problem

Millions quit their blood pressure medication because of a dry cough. A new peptide approach aims to fix that.

Captopril has been lowering blood pressure since the late 1970s. Fifty years later, researchers are still benchmarking new molecules against it — which tells you something about how solid its pharmacology is. It also tells you that nobody has replaced it. The cough alone has probably sent millions of patients to the pharmacy asking to switch.

What captopril actually does

The renin-angiotensin system (RAS) is the body’s main blood pressure dial. When pressure drops, the kidney releases renin, which sets off a chain reaction ending with angiotensin II — a molecule that tells blood vessels to constrict and kidneys to retain more sodium. Angiotensin-converting enzyme (ACE) is the step that makes angiotensin II, converting it from the inactive precursor angiotensin I.

Captopril blocks ACE. The result: less angiotensin II, lower blood pressure. It also prevents ACE from degrading bradykinin, a peptide that helps keep vessels relaxed. Both effects support cardiovascular health.

Here is the problem. ACE has two active regions — the N-domain and the C-domain. Captopril hits both. The C-domain handles most of the angiotensin I conversion. The N-domain is more involved in bradykinin metabolism. When bradykinin accumulates in lung tissue because ACE is blocked, it irritates the airways. That is the cough. About 10-20% of patients on captopril get it, and in some populations — particularly East Asian patients — the rate runs closer to 30-40%.

People stop their medication. This is a real clinical problem, not a footnote.

Block only the C-domain, and the theory holds that you preserve the blood pressure benefit while leaving bradykinin metabolism mostly intact — no cough.

A new class of ACE inhibitors — peptides

Bioactive peptides are short chains of amino acids, typically derived from natural sources — food proteins, fermented products, animal venoms. Some of them have been known to inhibit ACE for decades, but they tend to be less potent than pharmaceutical drugs and harder to characterize systematically.

Recent research used a different approach: virtual screening of an internal peptide database against the crystal structure of ACE’s C-domain. Two peptides came out of that process as candidates worth pursuing into the lab:

  • MSFLEHFLELK (referred to as PepDB_AHP1)
  • VWTNCYHLYPAH (referred to as PepDB_AHP4)

Both were then synthesized and tested in vitro against isolated ACE, using a standard substrate assay.

The molecular docking results

Before the lab work, the researchers ran molecular docking simulations — computational models predicting how each peptide fits into ACE’s binding pocket.

PeptideDocking scoreTotal interactionsHydrogen bonds
PepDB_AHP1 (MSFLEHFLELK)-9.4 kcal/mol225
PepDB_AHP4 (VWTNCYHLYPAH)-9.1 kcal/mol1612

Both docked with scores around -9 kcal/mol. Importantly, both made contact with residues specific to the C-domain — Val379, Val380, Glu376 — rather than residues shared between both ACE domains. That selectivity is the interesting part. PepDB_AHP4 formed 12 hydrogen bonds out of 16 total contacts. PepDB_AHP1 formed only 5 out of 22. Hydrogen bonds stabilize the molecule-enzyme complex, which goes some way toward explaining the potency difference that showed up in the lab.

What the IC50 numbers tell us — and what they don’t

The lab results confirmed that both peptides inhibit ACE. PepDB_AHP4 came in at an IC50 of 88.63 μM. PepDB_AHP1 was 331.2 μM.

To put those in perspective: captopril works in the nanomolar range — roughly three orders of magnitude more potent. These peptides are not replacing captopril. They are not even close yet. What they are is a starting point with some structurally meaningful properties.

The IC50 range fits within what has been reported for ACE inhibitory peptides from food sources — black tea derivatives (121-210 μM), walnut protein peptides (89-506 μM). So the numbers are not surprising. The selectivity profile is what makes them worth developing further.

The potency gap between the two peptides also tells a story. PepDB_AHP4’s richer hydrogen bonding network likely explains why it binds more tightly. That is a structure-activity relationship the researchers can work with — add more hydrogen-bonding residues, improve potency. That kind of lead optimization is routine chemistry once you have identified a binding scaffold that hits the right residues.

Why this matters for treatment adherence

Hypertension affects roughly 1.3 billion people globally and accounts for a large fraction of cardiovascular deaths. Many of those deaths are preventable with medication. But medication only works when people take it consistently, and a meaningful percentage of patients on ACE inhibitors do not.

The cough drives some of that discontinuation. ARBs (angiotensin receptor blockers) handle the problem by working downstream of ACE — they block the angiotensin II receptor rather than the enzyme. Cough rates on ARBs are much lower. But ARBs are not ACE inhibitors. Some clinicians prefer ACE inhibitors in specific contexts — patients with heart failure, diabetic nephropathy, post-MI management — partly because of evidence accumulated over decades of ACE inhibitor use.

A C-domain selective ACE inhibitor would be a different option: same mechanistic target as captopril, reduced cough liability. That distinction matters when choosing treatment for patients who do not tolerate current ACE inhibitors but for whom the prescriber has a reason to prefer ACE inhibition over ARB therapy.

What still needs to happen

The researchers are honest about where these peptides are in development. The list of remaining work is long:

  • Cytotoxicity testing in gut epithelial cells (Caco-2 is the standard model)
  • Stability testing in serum and simulated gastric conditions — peptides can be digested before they reach their target
  • Structural optimization: shortening sequences, adding hydrophobic groups, cyclizing the backbone to resist degradation
  • Animal studies to determine whether in vitro ACE inhibition translates to actual blood pressure reduction
  • Pharmacokinetic analysis before anything approaches human testing

The computational approach that identified these candidates is worth noting on its own terms. Virtual screening against a protein crystal structure, followed by targeted in vitro validation, is a cost-effective way to pull promising peptides out of a large database without running exhaustive physical experiments. The fact that both peptides held up in the lab — confirming ACE inhibition at measurable IC50 values — validates the screening methodology.

Captopril’s enduring position as a benchmark

Captopril’s binding mechanism has been studied in detail for decades: the thiol group coordinates with the ACE zinc ion, interactions with Glu411 and His387 stabilize the complex, and the binding kinetics are thoroughly characterized. New ACE inhibitors are still compared against it precisely because that level of mechanistic detail makes it a reliable reference point.

The new peptides don’t beat captopril. They don’t need to — not yet. What they establish is that it is possible to identify peptide sequences computationally that land in the C-domain binding pocket, engage the right residues, and inhibit the enzyme in a test tube. That is a foundation. What gets built on it depends on whether the optimization work pans out.

Frequently Asked Questions

What is captopril and how does it work?

Captopril is a drug that blocks angiotensin-converting enzyme (ACE), a protein that raises blood pressure by producing angiotensin II. By blocking ACE, captopril prevents blood vessel constriction and has been used to treat hypertension and heart failure since the early 1980s.

Why does captopril cause a dry cough?

ACE normally breaks down bradykinin in lung tissue. When ACE is blocked, bradykinin accumulates and irritates the airways, producing a persistent dry cough. About 10-20% of patients experience this, with higher rates in East Asian populations. It is a frequent reason people stop the medication.

What is an ACE inhibitory peptide?

A short amino acid sequence — often derived from food proteins, fermented products, or other natural sources — that can bind to ACE and slow its activity. These peptides are typically less potent than pharmaceutical ACE inhibitors but have attracted interest for their natural origin and potential for C-domain selectivity.

What does “selective C-domain inhibition” mean?

ACE has two active regions: the N-domain and the C-domain. The C-domain handles most of the conversion of angiotensin I to angiotensin II (the blood pressure effect). The N-domain is more involved in bradykinin degradation in the lungs. Blocking only the C-domain could theoretically reduce blood pressure without triggering the cough mechanism.

How does molecular docking work in drug discovery?

Researchers take a protein’s known crystal structure and run software that predicts how a drug or peptide candidate physically fits into the protein’s active site. The software generates a binding score reflecting estimated binding energy. Stronger (more negative) scores generally indicate tighter binding. Candidates with favorable scores then move to actual laboratory testing.

Will these peptides replace captopril?

No — not in the foreseeable future. Captopril works in the nanomolar range; the peptides described in current research inhibit ACE at micromolar concentrations, which is roughly 1000-fold less potent. They are lead compounds: starting structures that show the right binding interactions and can be chemically modified to improve potency over successive rounds of optimization.

What is the renin-angiotensin system (RAS)?

A hormonal cascade that regulates blood pressure and fluid balance. The kidney releases renin when pressure drops; renin triggers production of angiotensin I; ACE converts that to angiotensin II, which constricts blood vessels and prompts sodium retention. ACE inhibitors interrupt this cascade to lower blood pressure.

What tests would these peptides need before clinical use?

The standard path includes cytotoxicity screening, stability testing in simulated gut and blood environments, structural optimization, animal studies for actual blood pressure effects, pharmacokinetic analysis, and finally human clinical trials. The entire process typically runs across many years of development.

Are there natural sources of ACE inhibitory peptides?

Yes. Peptides with ACE inhibitory activity have been found in fermented dairy products, black tea, walnut protein, fish hydrolysates, and various plant sources. Most naturally occurring examples have IC50 values in the range of dozens to hundreds of micromolar — similar to the peptides discussed here. None of them approach the potency of captopril without structural modification.

Why is treatment adherence important for hypertension?

Hypertension usually has no symptoms until cardiovascular damage has occurred. Patients often feel fine without medication, which makes it easy to skip doses or stop treatment. Side effects like the ACE inhibitor cough give people a concrete reason to discontinue, and discontinuation translates directly into higher risk of heart attack, stroke, and kidney disease.

Comments are closed